Cencora Inc. closed $1.59 short of its 52-week high ($251.56), which the company reached on November 12th. Supported by world ...

In a report released yesterday, Steve Baxter from Wells Fargo maintained a Hold rating on Cencora (COR – Research Report), with a price ...

Summit Global Investments acquired a new stake in Cencora, Inc. (NYSE:COR – Free Report) in the 3rd quarter, ...

Analyst Charles Rhyee of TD Cowen maintained a Buy rating on Cencora (COR – Research Report), with a price target of $288.00. Charles ...

Drug distributor Cencora plans to buy Retina Consultants of America from Webster Equity Partners in a $4.6 billion deal.  | ...

Cencora is one of three leading domestic wholesalers of branded, generic, and specialty pharmaceutical products. With over $200 billion in annual US healthcare distribution sales, the company ...

Shares of Cencora, Inc. (NYSE:COR – Get Free Report) hit a new 52-week high during mid-day trading on Thursday following a stronger than expected earnings report. The stock traded as high as $250.42 ...

Cencora will potentially pay up to $500 million in aggregate contingent consideration in fiscal years 2027 and 2028.

Cencora, Inc.'s ( NYSE:COR ) dividend will be increasing from last year's payment of the same period to $0.55 on ...

Cencora, Inc. (NYSE: COR) today announced the appointment of Francois Mandeville as Executive Vice President, Strategy and M&A, and Pawan Verma as Executive Vice President, Chief Data and Information ...

Cencora, Inc. COR reported fourth-quarter fiscal 2024 adjusted earnings per share (EPS) of $3.34, which beat the Zacks ...

The city of Baltimore won $266 million in its lawsuit accusing top drug distributors McKesson and Cencora of fueling an ...